U.S. markets open in 9 hours 7 minutes
  • S&P Futures

    3,596.50
    -5.00 (-0.14%)
     
  • Dow Futures

    28,821.00
    +20.00 (+0.07%)
     
  • Nasdaq Futures

    10,977.75
    -57.75 (-0.52%)
     
  • Russell 2000 Futures

    1,671.40
    +1.60 (+0.10%)
     
  • Crude Oil

    81.61
    +2.12 (+2.67%)
     
  • Gold

    1,671.30
    -0.70 (-0.04%)
     
  • Silver

    19.20
    +0.17 (+0.87%)
     
  • EUR/USD

    0.9800
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1095
    -0.0071 (-0.64%)
     
  • USD/JPY

    144.9200
    +0.1910 (+0.13%)
     
  • BTC-USD

    19,143.51
    -163.97 (-0.85%)
     
  • CMC Crypto 200

    435.21
    -8.22 (-1.85%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    26,096.77
    +159.56 (+0.62%)
     

4 Penny Stocks Insiders Are Buying

·2 min read

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Calithera Biosciences

  • The Trade: Calithera Biosciences, Inc. (NASDAQ: CALA) Director Jonathan G Drachman acquired a total of 200000 shares at an average price of $0.86. The insider spent $171,900.00 to buy those shares.

  • What’s Happening: The company posted a narrower-than-expected Q3 loss.

  • What Calithera Biosciences Does: Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm is functioned through the region of US.

Liquidia

  • The Trade: Liquidia Corporation (NASDAQ: LQDA) General Counsel Russell Schundler acquired a total of 117908 shares shares at an average price of $4.21. The insider spent $496,834.09 to buy those shares.

  • What’s Happening: The FDA recently granted tentative approval to Liquidia’s Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms.

  • What Liquidia Does: Liquidia Corp, formerly Liquidia Technologies Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using PRINT technology to transform the lives of patients.

ARC Document Solutions

  • The Trade: ARC Document Solutions, Inc. (NYSE: ARC) Chairman, President and CEO Kumarakulasingam Suriyakumar acquired a total of 48117 shares at an average price of $3.00. To acquire these shares, it cost $144,475.41.

  • What’s Happening: The company recently reported Q3 results.

  • What ARC Document Solutions Does: ARC Document Solutions Inc is a global document solutions provider. The company's service offerings include managed print services (MPS), offsite services, archive and information management ( AIM), specialized color printing, Web-based document management applications, and equipment and supplies sales.

Value Exchange International

  • The Trade: Value Exchange International, Inc. (OTC: VEII) 10% owner Heng Fai Ambrose Chan acquired a total of 3199200 shares shares at an average price of $0.25. The insider spent $799,800.00 to buy those shares.

  • What’s Happening: The company’s shares have surged around 149% since the start of the year.

  • What Value Exchange International Does: Value Exchange International Inc is a US-based software company. The company through its subsidiaries provides customer-centric hardware and software system solutions for the retail industry in China, Hong Kong, and Philippines.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.